Pharmaceutical News News 13 August 2025 - 24 November 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On Wednesday, INM shares closed at $1.23, down almost 16% on the day, before surging about 22% after hours to around $1.50.Benzinga That momentum rolled into Thursday’s pre‑market session, where multiple market data sources showed gains of roughly 20–26%, with INM changing hands in the $1.49–$1.55 range on unusually high volume.Benzinga+2RTTNews+2 As regular trading gets underway, real‑time quote providers still show

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug Namodenoson, and confirmed that a pivotal Phase III trial in hepatocellular carcinoma (HCC) is now enrolling patients in multiple regions. GlobeNewswire+1 According to real‑time market data, Can-Fite’s American Depositary Receipts (ADRs) traded around $0.47 on November 18, up more than

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS) of 16.5 months vs. 9.2 months for sunitinib alone (HR=0.50; 95% CI 0.39–0.65; p<0.0001) and a 46% objective response rate vs. 26% on sunitinib monotherapy (p<0.0001). GlobeNewswire “It is a historic day for Cogent Biosciences and the GIST patient community,” CEO Andrew Robbins said, adding that the bezuclastinib combination “is poised to become the new standard of care” in second‑line

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)

QURE Stock Update and Analysis as of September 24, 2025 Latest News and Catalysts (September 2025) Historic Huntington’s Results: On September 24, 2025, uniQure revealed landmark Phase I/II trial results for its Huntington’s disease gene therapy AMT-130. In patients treated with a one-time injection of AMT-130, disease progression was significantly slowed – by about 75% over three years for those on the high dose reuters.com. Treated patients maintained far more of their motor and cognitive function compared to the expected decline in Huntington’s, which is an invariably progressive and fatal neurodegenerative disorder reuters.com reuters.com. Crucially, there are currently no approved drugs that slow Huntington’s disease, so these results